Capital World Investors
ACAD icon

Capital World Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital World Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,057,000
Closed -$16.1M – 550
2018
Q2 		$16.1M Sell
1,057,000
-4,076,000
-79% -$72.7M ﹤0.01% 475
2018
Q1 		$115M Buy
5,133,000
+2,305,000
+82% +$63.8M 0.03% 283
2017
Q4 		$85.2M Buy
2,828,000
+275,000
+11% +$8.79M 0.02% 309
2017
Q3 		$96.2M Hold
2,553,000
– – 0.02% 297
2017
Q2 		$71.2M Hold
2,553,000
– – 0.02% 319
2017
Q1 		$87.8M Sell
2,553,000
-950,000
-27% -$33.5M 0.02% 298
2016
Q4 		$101M Sell
3,503,000
-261,000
-7% -$6.91M 0.03% 281
2016
Q3 		$120M Hold
3,764,000
– – 0.03% 266
2016
Q2 		$122M Buy
3,764,000
+430,000
+13% +$14.4M 0.03% 259
2016
Q1 		$93.2M Buy
3,334,000
+590,000
+22% +$12.9M 0.03% 281
2015
Q4 		$97.8M Sell
2,744,000
-377,000
-12% -$13.3M 0.03% 284
2015
Q3 		$103M Sell
3,121,000
-300,756
-9% -$12.5M 0.03% 284
2015
Q2 		$143M Sell
3,421,756
-29,644
-0.9% -$1.15M 0.04% 273
2015
Q1 		$112M Buy
3,451,400
+2,108,400
+157% +$72.5M 0.03% 294
2014
Q4 		$42.6M Buy
1,343,000
+530,203
+65% +$15M 0.01% 382
2014
Q3 		$20.1M Buy
812,797
+412,797
+103% +$9.65M 0.01% 431
2014
Q2 		$9.04M Hold
400,000
– – ﹤0.01% 485
2014
Q1 		$9.73M Buy
400,000
+150,000
+60% +$3.79M ﹤0.01% 472
2013
Q4 		$6.25M Hold
250,000
– – ﹤0.01% 469
2013
Q3 		$6.87M Buy
+250,000
New +$5.23M ﹤0.01% 463

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Capital World Investors's ACAD Position: Q3 2018 in Review

Capital World Investors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 1,057,000 shares — an estimated $16.1M sold.

Capital World Investors first reported a position in ACAD in Q3 2013 and held it in 20 quarters. The position peaked at $143M in Q2 2015. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

  • Capital World Investors reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Capital World Investors sold 1,057,000 Acadia Pharmaceuticals shares in Q3 2018, an estimated $16.1M.
  • Capital World Investors first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 20 quarters.
  • Capital World Investors's Acadia Pharmaceuticals position peaked at $143M in Q2 2015.
  • 184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Capital World Investors's 13F filing for Q3 2018, filed 14 Nov 2018.